Currently Viewing:
COA 2017-ONCOLOGY PAYMENT REFORM
David Merrill and John Robinson Discuss Barriers to APMs, Factors of Interest
January 15, 2018
Dr Jeff Patton Discusses Preparing for OCM, Seeing Improved Outcomes and Savings
January 12, 2018
Dr Peter Aran on Involving Providers in Development Process of New Reimbursement Models
January 11, 2018
Sarah Cevallos on Her Advice for Practices Looking to Participate in OCM
January 10, 2018
Dr Roger Brito: What Patients Should Know About Alternative Payment Models, OCM
January 09, 2018
Currently Reading
Dr Mark Fendrick on Indication-Based Drug Pricing in Cancer Care
January 07, 2018
Judy Berger on What Southwest Airlines Is Doing in Oncology
January 04, 2018
Terrill Jordan Discusses Making Refinements in Year 2 of OCM
January 03, 2018
Sarah Cevallos: Physicians Need More Data to Determine if 2-Sided Risk is Appropriate
December 26, 2017
Terrill Jordan: Year 1 Feedback on OCM
December 22, 2017
Dr Lucio Gordan: Improving Population Health Through Alternative Payment Models
December 08, 2017
Dr Ira Klein on Pharmaceutical Interest in Alternative Payment Models
December 07, 2017
Dr Ira Klein Outlines the Biggest Challenge of Value-Based Drug Pricing
November 05, 2017
Stakeholders Weigh-in on Payment Reform in Cancer Care
October 25, 2017
The Commercial Payer OCM Experience: Year 1
October 25, 2017
Terrill Jordan: Education and Data Are Key for OCM Success
October 25, 2017
Physicians Need Clearer Metrics Before Taking on 2-Sided Risk
October 25, 2017
Dr Jeff Patton Highlights Challenges Encountered With Implementing OCM
October 24, 2017
Dr Lucio Gordan: How Practices and Payers Work Together to Implement OCM
October 24, 2017

Dr Mark Fendrick on Indication-Based Drug Pricing in Cancer Care

The fact that you have certain drugs that treat numerous cancers, and that they may treat 1 cancer different or better than another, would suggest that we should probably have differential pricing models, said A. Mark Fendrick, MD, director of the Center for Value-Based Insurance Design at the University of Michigan.


The fact that you have certain drugs that treat numerous cancers, and that they may treat 1 cancer different or better than another, would suggest that we should probably have differential pricing models, said A. Mark Fendrick, MD, director of the Center for Value-Based Insurance Design at the University of Michigan.

Transcript (slightly modified)

The issue of indication-based pricing is 1 response to tremendous pressure about what we’re doing with cost for drugs, particularly in cancer. So, we want to try to get to a situation where we’re actually paying appropriate amounts for drugs that work well. It’s not unique to cancer, but the fact that you have certain drugs that treat numerous cancers, and that it may treat 1 cancer different or better than another, would suggest that we should probably have differential pricing models. So, we’ve advocated for indication-based pricings for drugs for quite some time, only based on really hard, clinical evidence. I think, while it’s very complicated and understanding it might be difficult to move forward, but if people can understand that there are many parameters that you determine a value-based price or an indication-based price.  The 3 that come to the top of my mind for me are:
  • First is the severity of the condition, so cancer tends to be a higher, say then toe fungus or allergies.
  • Second is how well the drug actually works, so does it completely cure you, does it slow the progression, or does it only treat your symptoms.
  • The last, which makes this indication-based pricing so complicated in my eyes, is actually if they’re alternative therapies. So, if there’s obviously alternative therapies that are less expensive, then you can argue for a lower indication-based price.
If you put just those 3 variables together, you understand that now you have a Rubik’s cube, making it so hard, as opposed as 1 price for everything. Now we’re saying we might price it based on what you’re using it for, how well it works, and whether there are alternatives, which is why we would say don’t move ahead with indication-based pricing, or value-based pricing, but understand that there are a lot of variables that need to be considered before we go too far or too fast.

 
Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!